Literature DB >> 19953117

Clinical prognostic factors in multiple sclerosis: a natural history review.

Alexandra Degenhardt1, Sreeram V Ramagopalan, Antonio Scalfari, George C Ebers.   

Abstract

This Review summarizes the natural history studies on multiple sclerosis (MS) that have evaluated prognostic factors. Reassessment of prognostic factors is warranted, as our ability to offer patients a reliable prognosis is limited, yet we rely on this knowledge to appropriately design clinical trials and interpret their results. The selection criteria for studies to review included a geographical referral base, duration of at least 9 years, prospective design, and populations of at least 100 patients with MS. For all forms of MS combined, negative prognostic factors included progressive disease, and disability at 2 and 5 years. In relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) combined, negative prognostic factors were the onset of progression, a higher relapse rate, greater disability in the first 5 years, a shorter interval to the second relapse, and the involvement of more systems. Additional negative factors include a shorter time to progression in SPMS and a faster rate of disability in the first 2 and 5 years in primary progressive MS (PPMS). Onset of progression, relapse rate and disability in the initial 5 years could be fruitful therapeutic targets; however, longer-term clinical trials will be required to justify these end points.

Entities:  

Mesh:

Year:  2009        PMID: 19953117     DOI: 10.1038/nrneurol.2009.178

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  89 in total

1.  A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials.

Authors:  M P Amato; G Ponziani; M L Bartolozzi; G Siracusa
Journal:  J Neurol Sci       Date:  1999-10-15       Impact factor: 3.181

2.  The natural history of untreated multiple sclerosis in Iceland. A total population-based 50 year prospective study.

Authors:  John Benedikz; Magnūs Stefánsson; Jūlíus Guomundsson; Aoalbjörg Jónasdóttir; Ragnheiour Fossdal; Jeff Gulcher; Kāri Stefánsson
Journal:  Clin Neurol Neurosurg       Date:  2002-07       Impact factor: 1.876

3.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

4.  Prevalence of multiple sclerosis in Belgrade, Yugoslavia.

Authors:  T Pekmezovic; M Jarebinski; J Drulovic; N Stojsavljevic; Z Levic
Journal:  Acta Neurol Scand       Date:  2001-12       Impact factor: 3.209

5.  Studies on the natural history of multiple sclerosis. 6. Clinical and laboratory findings at first diagnosis.

Authors:  J F Kurtzke; G W Beebe; B Nagler; T L Auth; L T Kurland; M D Nefzger
Journal:  Acta Neurol Scand       Date:  1972       Impact factor: 3.209

6.  The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis.

Authors:  D A Cottrell; M Kremenchutzky; G P Rice; W Hader; J Baskerville; G C Ebers
Journal:  Brain       Date:  1999-04       Impact factor: 13.501

7.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

8.  Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg.

Authors:  T Broman; O Andersen; L Bergmann
Journal:  Acta Neurol Scand       Date:  1981-01       Impact factor: 3.209

9.  The natural history of multiple sclerosis: a regional study with some longitudinal data.

Authors:  D H Miller; R W Hornabrook; G Purdie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

10.  Multiple sclerosis after age 50.

Authors:  J Noseworthy; D Paty; T Wonnacott; T Feasby; G Ebers
Journal:  Neurology       Date:  1983-12       Impact factor: 9.910

View more
  39 in total

Review 1.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

2.  Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation.

Authors:  Ming Zhao; Dingya Sun; Yangtai Guan; Zhihong Wang; Daoqian Sang; Mingdong Liu; Yingyan Pu; Xue Fang; Dan Wang; Aijun Huang; Xiaoying Bi; Li Cao; Cheng He
Journal:  J Neurosci       Date:  2016-08-31       Impact factor: 6.167

3.  Multiple sclerosis and rehabilitation: an overview of the different rehabilitation settings.

Authors:  Andrea Tacchino; Giampaolo Brichetto; Paola Zaratin; Mario Alberto Battaglia; Michela Ponzio
Journal:  Neurol Sci       Date:  2017-09-15       Impact factor: 3.307

Review 4.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

5.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

Authors:  Amit Bar-Or; Ralf Gold; Ludwig Kappos; Douglas L Arnold; Gavin Giovannoni; Krzysztof Selmaj; John O'Gorman; Monica Stephan; Katherine T Dawson
Journal:  J Neurol       Date:  2013-09       Impact factor: 4.849

6.  Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

Authors:  Michael Hutchinson; Robert J Fox; David H Miller; J Theodore Phillips; Mariko Kita; Eva Havrdova; John O'Gorman; Ray Zhang; Mark Novas; Vissia Viglietta; Katherine T Dawson
Journal:  J Neurol       Date:  2013-06-08       Impact factor: 4.849

7.  Thyroid hormone alleviates demyelination induced by cuprizone through its role in remyelination during the remission period.

Authors:  Mao Zhang; Xiao L Zhan; Zi Y Ma; Xing S Chen; Qi Y Cai; Zhong X Yao
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-10

8.  Disability in multiple sclerosis: a reference for patients and clinicians.

Authors:  Ilya Kister; Eric Chamot; Amber R Salter; Gary R Cutter; Tamar E Bacon; Joseph Herbert
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

Review 9.  Using EAE to better understand principles of immune function and autoimmune pathology.

Authors:  Manu Rangachari; Vijay K Kuchroo
Journal:  J Autoimmun       Date:  2013-07-09       Impact factor: 7.094

10.  Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.

Authors:  Cecilia Smith Simonsen; Heidi Øyen Flemmen; Line Broch; Cathrine Brunborg; Pål Berg-Hansen; Stine Marit Moen; Elisabeth Gulowsen Celius
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.